Management of diastolic heart failure - A practical review of pathophysiology and treatment trial data

International Journal of Clinical Practice

Volumn 59, Issue 10, 2005, Pages 1239-1246

  Wu, E B ^a   Yu, C M ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ACEI; Angiotensin receptor blockers; Diastolic heart failure; Pathophysiology of heart failure

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IBOPAMINE; IRBESARTAN; LOSARTAN; MCC 135; MILRINONE; MORPHINE; NEBIVOLOL; NITRIC ACID DERIVATIVE; OXYGEN; PERINDOPRIL; PIPERANOMETOZINE; RAMIPRIL; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; BIOLOGICAL MARKER;

ANXIETY; BEHAVIOR MODIFICATION; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; LIFESTYLE; MEDICAL PRACTICE; META ANALYSIS; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; BLOOD; CONGESTIVE HEART FAILURE; DIASTOLE; DRUG COMBINATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; DIASTOLE; DIURETICS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; TREATMENT OUTCOME;

EID: 33644834177     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00642.x     Document Type: Review

References (72)

1. Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med 2004; 351: 1097-105.
2. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004; 55: 373-94.
3. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2001; 37: 1042-8.
4. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003;289: 194-202.
5. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-74.
6. Vasan R, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948-55.
7. Senni M, Tribouilloy CM, Rodeheffer RJ et al. Congestive heart failure in the community: A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-9.
8. Cleland JG, Swedberg K, Follath F et al. The EuroHeart failure survey programme: A survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-63.
9. Sanderson JE, Chan S, Chan WWM et al. The aetiology of heart failure in the Chinese population of Hong Kong -a prospective study of 730 consecutive patients. Int J Cardiol 1995; 51: 29-35.
10. Yip GWK, Ho PPY, Woo KS et al. Comparison of frequencies of left ventricular systolic and diastolic heart failure in Chinese living in Hong Kong. Am J Cardiol 1999; 84: 563-7.
11. Sanderson JE, Tse TF. Heart failure: A global disease requiring a global response. Heart 2003; 89: 585-6.
12. O'Conner CM, Gattis WA, Shaw L, Cuffe MS, Califf RM. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 2000; 86: 863-7.
13. Judge KW, Pawitan Y, Caldwell J, Gersh BJ, Kennedy JW. Congestive heart failure symptoms in patients with preserved left ventricular systolic function: Analysis of the CASS registry. J Am Coll Cardiol 1991; 18: 377-82.
14. Dougherty AH, Naccarelli GV, Gray EL et al. Congestive heart failure with normal systolic function. Am J Cardiol 1984; 54: 778-82.
15. Soufer R, Wohlgelernter D, Vita NA et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol 1985; 55: 1032-6.
16. Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relationship. Circ Res 1989; 64: 827-52.
17. Yip GWK, Wang M, Zhang Y et al. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: Time for a redefinition. Heart 2002; 87: 121-5.
18. Petrie MC, Caruana L, Berry C et al. Diastolic heart failure or heart failure caused by subtle left ventricular systolic dysfunction. Heart 2002; 87: 29-31.
19. Sanderson JE. Diastolic heart failure: Fact or fiction? Heart 2003; 89: 1281-2.
20. The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005). Eur Heart J 2005; 26: 1115-40.
21. Yip GWK, Zhang Y, Tan PY et al. Left ventricular long-axis changes in early diastole and systole: Impact of systolic function on diastole. Clin Sci 2002; 102: 515-22.
22. Yu CM, Sanderson JE. Right and left ventricular diastolic function in patients with and without heart failure: Effects of age, sex, heart rate, and respiration on Doppler-derived measurements. Am Heart J 1997; 134: 426-34.
23. Hunt SA, Baker DW, Chin MH et al. Guidelines for the evaluation and management ofAchronic heart failure in adult: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2001; 38: 2101-13.
24. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eu Heart J 1998; 19: 990-1003.
25. Vasan RS, Ley D. Defining diastolic heart failure: A call for standardized diagnostic criteria. Circulation 2000; 101: 2118-21.
26. Baughman KL. B-type natriuretic peptide: A window to the heart. N Engl J Med 2002; 347: 158-9.
27. Dao Q, Krishnaswamy P, Kazanegra R et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. J Am Coll Cardiol 2001; 37: 379-85.
28. Vasan RS, Benjamin EJ, Larson MG et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham Heart Study. JAMA 2002; 288: 1252-9.
29. Landray MJ, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross sectional study. BMJ 2000; 320: 985-6.
30. Krishnaswamy P, Lubien E, Clopton P et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274-9.
31. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004; 164: 1978-84.
32. Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
33. Choy AM, Darbar D, Lang CC et al. Detection of left ventricular dysfunction after acute myocardial infarction: Comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994; 72: 16-22.
34. Gaasch WH, Schick EC, Zile MR. Management of left ventricular diastolic dysfunction. In: Smith TW, ed. Cardiovascular Therapeutics. A Companion to Braunwald's Heart Disease Philadelphia: W.B. Saunders 1996, 237-42.
35. Kramer K, Kirkman P, Kitzman D, Little WC. Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization. Am Heart J 2000; 40: 451-5.
36. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777-81.
37. Flather MD, Shibata MC, Coats AJS et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure. Eur Heart J 2005; 26: 215-25.
38. Zile M, Gaasch W, Little W et al. A phase II, double blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): Rationale and design. J Card Fail (US) 2004; 10: 193-9.
39. Cleland JGF, Tendera M, Adams J et al. Perindopril for elderly people with chronic heart failure: The PEP-CHF study. Eur J Heart Fail 1999; 1: 211-7.
40. Sanderson JE. Re: PEP-CHF Study [Letter]. Eur J Heart Fail 2000; 2: 117.
41. Bergstrom A, Andersson B, Edner M et al. Carvedilol improves diastolic dysfunction in patients with diastolic heart failure. Circulation 2001; 104 (Suppl. II): II-7.
42. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. JAMA 2003; 289: 2560-72.
43. Kostis JB, Davis BR, Cutler J et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Res Group. JAMA 1997; 278: 212-6.
44. Hauptman PJ. Measurement of end points in heart failure trials. Jousting at windmills? Mt Sinai J Med 2004; 71: 298-304.
45. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction. Am J Cardiol 1988; 61: 501-9.
46. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
47. Feldman AM, Bristow MR, Parmley WW et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993; 149-55.
48. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75.
49. Hampton JR, van Veldhuisen DJ, Kleber FX et al. Randomized study of effects of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997; 349: 971-7.
50. Packer M, Colucci WS, Sackner-Bernstein JD et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996; 94: 2793-9.
51. Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 2002; 8 (Suppl. 6): S465-71.
52. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003.
53. Diez J, Querejeta R, Lopez B et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-7.
54. Warner JG Jr, Metzger DC, Kitzman DW et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and hypertensive response to exercise. J Am Coll Cardiol 1999; 33: 1567-72.
55. Schmieder RE, Schlaich MP, Klingbeil AU. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-13.
56. Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 1995; 91: 698-706.
57. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: Comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95: 2007-14.
58. Setaro JF, Zaret BL, Schulman DS et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990; 66: 981-6.
59. Terpsta WF, May JF, Smit AJ et al. Long term effects of amlodipine and lisinopril on left ventricular mass and diastolic dysfunction in the elderly previously in treated hypertensive patients: The ELVERA trial. J Hypertens 2001; 19: 303-9.
60. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-Left Ventricular Hypertrophy Study. Circulation 2003; 108: 1831-8.
61. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22: 17-22.
62. Thohan V, Torre-Amione G, Koerner MM. Aldosterone antagonism and congestive heart failure: A new look at an old therapy [Review]. Curr Opin Cardiol 2004; 19: 301-8.
63. Philblin EF, Rocco RA, Lindenmuth MW et al. Systolic versus diastolic heart failure in community practice: Clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000; 109: 605-13.
64. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
65. Ventura HO, Loyalka P, Smart FW. Treatment of hypertensive patient with microvascular angina. Curr Opin Cardiol 1999; 14: 370-4.
66. Grandi AM, Imperiale D, Santillo R et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40: 647-52.
67. Mottram PM, Haluska B, Leano R et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110: 558-65.
68. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler echocardiographic study (SWEDIC). Eur J Heart Fail 2004; 6: 453-61.
69. Schillaci G, Pasqualini L, Vaudo G et al. Effect of body weight changes on 24-hour blood pressure and left ventricular mass in hypertension: A 4-year follow up. Am J Hypertens 2003; 16: 634-9.
70. Turner MJ, Spina RJ, Kohrt WM et al. Effect of endurance exercise training on left ventricular size and remodeling in older adults with hypertension. J Gerontol a Biol Sci Med Sci 2000; 55: 245-51.
71. Kitzman DW, Brubaker PH, Anderson RA et al. Exercise training improves aerobic capacity in elderly patients with diastolic heart failure: A randomized, controlled trial [Abstract]. Circulation 1999; 100: 296.
72. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.